Which Comes First, Nonalcoholic Fatty Liver Disease or Arterial Hypertension?

被引：3

作者：

Golubeva, Julia A. ^{[1
]}

Sheptulina, Anna F. ^{[1
,2
]}

Elkina, Anastasia Yu. ^{[1
,3
]}

Liusina, Ekaterina O. ^{[1
]}

Kiselev, Anton R. ^{[4
]}

Drapkina, Oxana M. ^{[1
,2
]}

机构：

[1] Natl Med Res Ctr Therapy & Prevent Med, Dept Fundamental & Appl Aspects Obes, Moscow 101990, Russia

[2] AI Evdokimov Moscow State Univ Med & Dent, Dept Therapy & Prevent Med, Moscow 127473, Russia

[3] Saratov State Med Univ, Dept Intermediate Level Therapy, Saratov 410012, Russia

[4] Natl Med Res Ctr Therapy & Prevent Med, Coordinating Ctr Fundamental Res, Moscow 101990, Russia

来源：

BIOMEDICINES | 2023年 / 11卷 / 09期

基金：

俄罗斯科学基金会;

关键词：

non-alcoholic fatty liver disease; hypertension; steatohepatitis; BLOOD-PRESSURE; INSULIN-RESISTANCE; INCIDENT HYPERTENSION; METABOLIC SYNDROME; RISK-FACTORS; CARDIOVASCULAR-DISEASE; ADIPOSE-TISSUE; FETUIN-A; ASSOCIATION; STEATOHEPATITIS;

D O I：

10.3390/biomedicines11092465

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Non-alcoholic fatty liver disease (NAFLD) and arterial hypertension (AH) are widespread noncommunicable diseases in the global population. Since hypertension and NAFLD are diseases associated with metabolic syndrome, they are often comorbid. In fact, many contemporary published studies confirm the association of these diseases with each other, regardless of whether other metabolic factors, such as obesity, dyslipidemia, and type 2 diabetes mellites, are present. This narrative review considers the features of the association between NAFLD and AH, as well as possible pathophysiological mechanisms.

引用

页数：25

共 50 条

[31] Diabetes mellitus and fatty liver disease: Which comes first?
Alavian, Seyed Moayed
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2010, 8 (03) : 130 - 131
[32] Nonalcoholic Fatty Liver Disease
Law, Kathryn
Brunt, Elizabeth M.
CLINICS IN LIVER DISEASE, 2010, 14 (04) : 591 - +
[33] Rosiglitazone treatment in nondiabetic subjects with nonalcoholic fatty liver disease
Saryusz-Wolska, Malgorzata
Szymanska-Garbacz, Elektra
Jablkowski, Maciej
Bialkowska, Jolanta
Pawlowski, Maciej
Kwiecinska, Ewa
Omulecka, Aleksandra
Borkowska, Anna
Ignaczak, Anna
Loba, Jerzy
Czupryniak, Leszek
POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2011, 121 (03): : 61 - 65
[34] Nonalcoholic Fatty Liver Disease and Metabolic Syndrome
Kim, Donghee
Touros, Alexis
Kim, W. Ray
CLINICS IN LIVER DISEASE, 2018, 22 (01) : 133 - +
[35] Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease
Wattacheril, Julia
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2020, 49 (01) : 141 - +
[36] Hyperferritinemia in patients with nonalcoholic fatty liver disease
Barros, Raffaelle K.
Cotrim, Helma Pinchemel
Daltro, Carla H.
Oliveira, Yanaihara A.
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2017, 63 (03): : 284 - 289
[37] Prevalence of Nonalcoholic Fatty Liver Disease and Economy
Zhu, Jin-Zhou
Dai, Yi-Ning
Wang, Yu-Ming
Zhou, Qin-Yi
Yu, Chao-Hui
Li, You-Ming
DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (11) : 3194 - 3202
[38] Risk factors in nonalcoholic fatty liver disease
Ko, Eunji
Yoon, Eileen L.
Jun, Dae Won
CLINICAL AND MOLECULAR HEPATOLOGY, 2023, 29 : S79 - S85
[39] The role of complement in nonalcoholic fatty liver disease
Guo, Zhenya
Fan, Xiude
Yao, Jianni
Tomlinson, Stephen
Yuan, Guandou
He, Songqing
FRONTIERS IN IMMUNOLOGY, 2022, 13
[40] Insulin Resistance in Nonalcoholic Fatty Liver Disease
Bugianesi, E.
Moscatiello, S.
Ciaravella, M. F.
Marchesini, G.
CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (17) : 1941 - 1951

← 1 2 3 4 5 →